TheBrief.Health
ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.
500 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af TheBrief.Health-fællesskabet!